Cargando…
CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication
AIM: To evaluate the impact of cytochrome P450 2C19 (CYP2C19) and interleukin-1β (IL-1β) polymorphisms on the efficacy of Helicobacter pylori (H. pylori) eradication by using rabeprazole-based hybrid therapy. METHODS: A total of 88 H. pylori-infected patients were recruited to receive 14-d of hybrid...
Autores principales: | Lin, Tsung-Jung, Lee, Hsi-Chang, Lin, Chih-Lin, Wang, Chung-Kwe, Chen, Kuan-Yang, Wu, Deng-Chyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212610/ https://www.ncbi.nlm.nih.gov/pubmed/30397607 http://dx.doi.org/10.12998/wjcc.v6.i12.514 |
Ejemplares similares
-
Levofloxacin-Amoxicillin/Clavulanate-Rabeprazole versus a Standard Seven-Day Triple Therapy for Eradication of Helicobacter pylori Infection
por: Chen, Ming-Cheh, et al.
Publicado: (2014) -
Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori
por: Wu, Meng-Chieh, et al.
Publicado: (2017) -
Performance of Routine Helicobacter pylori Invasive Tests in Patients with Dyspepsia
por: Lee, Hsi-Chang, et al.
Publicado: (2013) -
Esomeprazole- or rabeprazole-based triple therapy eradicated Helicobacter pylori comparably regardless of clarithromycin susceptibility and CYP2C19 genotypes
por: Okimoto, Tadayoshi, et al.
Publicado: (2016) -
Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori
por: Chen, Xing Xing, et al.
Publicado: (2022)